[HTML][HTML] T790M and acquired resistance of EGFR TKI: a literature review of clinical reports
C Ma, S Wei, Y Song - Journal of thoracic disease, 2011 - ncbi.nlm.nih.gov
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as gefitinib
and erlotinib are promising therapies for patients with advanced non-small-cell lung cancer …
and erlotinib are promising therapies for patients with advanced non-small-cell lung cancer …
Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors
C Rolfo, E Giovannetti, DS Hong, T Bivona… - Cancer treatment …, 2014 - Elsevier
Introduction Treatment with epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) yields tumour responses in non-small cell lung cancer (NSCLC) patients …
inhibitors (TKIs) yields tumour responses in non-small cell lung cancer (NSCLC) patients …
[HTML][HTML] Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib
T Katayama, J Shimizu, K Suda, R Onozato… - Journal of Thoracic …, 2009 - Elsevier
Introduction The efficacy of high-dose (1250 mg/d) gefitinib for the treatment of
leptomeningeal metastasis in a patient with lung cancer harboring a mutation in the …
leptomeningeal metastasis in a patient with lung cancer harboring a mutation in the …
Bayesian adaptive randomization designs for targeted agent development
Background With better understanding of the disease's etiology and mechanism, many
targeted agents are being developed to tackle the root cause of problems, hoping to offer …
targeted agents are being developed to tackle the root cause of problems, hoping to offer …
Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a …
S Watanabe, J Tanaka, T Ota, R Kondo, H Tanaka… - BMC cancer, 2011 - Springer
Background Gefitinib was the first epidermal growth factor receptor-tyrosine kinase inhibitor
(EGFR-TKI) approved for the treatment of advanced non-small cell lung cancer (NSCLC) …
(EGFR-TKI) approved for the treatment of advanced non-small cell lung cancer (NSCLC) …
Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects
G Bronte, C Rolfo, E Giovannetti, G Cicero… - Critical reviews in …, 2014 - Elsevier
Gefitinib and erlotinib are the two anti-epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors (TKIs) approved for treatment of advanced NSCLC patients. These drugs …
kinase inhibitors (TKIs) approved for treatment of advanced NSCLC patients. These drugs …
Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer
K Kaira, T Naito, T Takahashi, E Ayabe, R Shimoyama… - Lung Cancer, 2010 - Elsevier
PURPOSE: The use of erlotinib after gefitinib failure in patients with non-small cell lung
cancer (NSCLC) is not clearly clarified in clinical practice. We sought to compile the …
cancer (NSCLC) is not clearly clarified in clinical practice. We sought to compile the …
EGFR tyrosine kinase inhibitors beyond focal progression obtain a prolonged disease control in patients with advanced adenocarcinoma of the lung
F Conforti, C Catania, F Toffalorio, M Duca, G Spitaleri… - Lung Cancer, 2013 - Elsevier
Introduction Recent data show that EGFR pathway and its inhibition maintain their role after
progression of disease during EGFR TKI therapy in NSCLCs. We conducted a retrospective …
progression of disease during EGFR TKI therapy in NSCLCs. We conducted a retrospective …
[HTML][HTML] A phase II study of concurrent chemoradiotherapy and erlotinib for inoperable esophageal squamous cell carcinoma
C Zhao, L Lin, J Liu, R Liu, Y Chen, F Ge, R Jia, Y Jin… - Oncotarget, 2016 - ncbi.nlm.nih.gov
Cisplatin-based concurrent chemoradiotherapy for patients with unresectable, locally
advanced esophageal squamous cell carcinoma (ESCC) is associated with significant …
advanced esophageal squamous cell carcinoma (ESCC) is associated with significant …
Mechanisms of resistance to epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small-cell lung cancer: clinical and molecular …
A Pallis, E Briasoulis, H Linardou… - Current medicinal …, 2011 - ingentaconnect.com
Non-Small-Cell Lung Cancer (NSCLC) with somatic mutations of the epidermal growth
factor receptor (EGFR) is anticipated to respond to small-molecule tyrosine kinase inhibitors …
factor receptor (EGFR) is anticipated to respond to small-molecule tyrosine kinase inhibitors …